TriSalus Life Sciences (TLSI) Projected to Announce Earnings on Tuesday

Posted by Brian Himes on Nov 3rd, 2026

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect TriSalus Life Sciences to post earnings of ($0.14) per share and revenue of $14.02 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million. On average, analysts expect TriSalus Life Sciences to post ($0.53) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI traded down $0.07 during trading hours on Tuesday, hitting $3.56. The stock had a trading volume of 35,097 shares, compared to its average volume of 291,148. The company has a 50 day simple moving average of $4.40 and a two-hundred day simple moving average of $4.41. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95. The firm has a market capitalization of $219.45 million, a price-to-earnings ratio of -2.70 and a beta of 0.50.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TLSI. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd. HC Wainwright raised their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Finally, Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.20.

Read Our Latest Report on TLSI

TriSalus Life Sciences Company Profile

(Get Free Report)

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.